J&J Rides Consumer Health ‘Growth Annuity’ As Rx, Device Divisions Slow

 
• By Eileen Francis

Johnson & Johnson’s second-quarter U.S. OTC sales jumped nearly 16% on the return of recalled brands and Worldwide Group Chairman Peterson says J&J expects the consumer business to grow “increasingly” more robust.

Johnson &Johnson’s consumer health product business again provides a “growth annuity” as a reliable revenue driver even when sales slump in the more volatile Rx drug and medical device markets, says J&J Worldwide Group Chairman Sandra Peterson.

J&J expects its consumer business, which includes the Tylenol, Motrin and Zyrtec OTC brands manufactured by its McNeil Consumer Healthcare subsidiary, to grow more robust as the firm continues returning recalled products to stores,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Asia